Brainsway (BWAY) Expected to Announce Earnings on Wednesday

Brainsway (NASDAQ:BWAY) is projected to post its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Brainsway to post earnings of $0.11 per share and revenue of $14.0180 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 8:30 AM ET.

Brainsway Trading Down 2.2%

Shares of NASDAQ BWAY opened at $23.18 on Wednesday. The stock’s 50-day moving average is $11.54 and its 200 day moving average is $9.24. The stock has a market cap of $454.56 million, a price-to-earnings ratio of 77.27 and a beta of 1.20. Brainsway has a 1-year low of $7.84 and a 1-year high of $26.63.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Northland Securities set a $15.00 price objective on shares of Brainsway in a report on Thursday, January 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a research report on Monday, December 29th. Wall Street Zen lowered shares of Brainsway from a “buy” rating to a “hold” rating in a research report on Friday, January 23rd. Finally, HC Wainwright lifted their price objective on Brainsway from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Institutional Trading of Brainsway

Institutional investors have recently modified their holdings of the company. ARK Investment Management LLC purchased a new stake in shares of Brainsway in the fourth quarter worth $2,422,000. UBS Group AG boosted its stake in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after purchasing an additional 60,877 shares in the last quarter. Two Sigma Investments LP grew its position in Brainsway by 25.2% during the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after purchasing an additional 20,706 shares during the last quarter. Millennium Management LLC increased its stake in Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after purchasing an additional 16,354 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in Brainsway in the fourth quarter worth about $245,000. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.